Article Figures & Tables
Figures
Fig. 1: Patterns of use among current users of rofecoxib and celecoxib who had an acute myocardial infarction (MI).
Fig. 2: Adjusted rate ratios as a function of time after treatment is discontinuted.
Tables
Table 1.
Table 2.
Table 3.
In this issue
Article tools
Respond to this article
Jump to section
Related Articles
Cited By...
- COX2/mPGES1/PGE2 pathway regulates PD-L1 expression in tumor-associated macrophages and myeloid-derived suppressor cells
- Duration of Treatment With Nonsteroidal Anti-Inflammatory Drugs and Impact on Risk of Death and Recurrent Myocardial Infarction in Patients With Prior Myocardial Infarction: A Nationwide Cohort Study
- Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetes
- Drug drug interactions between antithrombotic medications and the risk of gastrointestinal bleeding
- Cardiac risks with COX-2 inhibitors
- Celecoxib Prevents Neuroblastoma Tumor Development and Potentiates the Effect of Chemotherapeutic Drugs In vitro and In vivo
- Risks versus benefits of cyclooxygenase-2-selective nonsteroidal antiinflammatory drugs.
- Balancing the cyclooxygenase portfolio.
More in this TOC Section
Similar Articles
